Histopathology Summary

• Muscularis propria is free (confirms non-muscle invasive)

Staging & Risk Stratification

Next Line of Management

1. Re-TURBT (Mandatory - Top Priority)

• The initial TURBT may have incompletely resected T1 disease
• Residual T1 tumor is found in 30-80% of cases at re-TURBT
• Re-TURBT upstages ~10-15% of T1 LG to muscle-invasive disease (T2), which completely changes management
• Adequate muscularis propria in the specimen is required for confident staging - here Sp2 (deep biopsy) showed no muscle invasion, which is reassuring, but formal re-TURBT is still standard practice

2. Intravesical BCG Therapy (Post-Re-TURBT)

• Intravesical BCG (Bacillus Calmette-Guerin) induction + maintenance is the standard adjuvant therapy for T1 disease
• Standard regimen: 6-week induction course followed by 3-week maintenance at 3, 6, 12, 18, 24, 30, and 36 months (Lamm protocol - 3-year full maintenance)
• BCG reduces recurrence and, importantly, progression to muscle-invasive disease
• If BCG is unavailable (shortage), intravesical Gemcitabine + Docetaxel (Gem/Doce) is the preferred alternative per AUA 2024

3. Cystoscopy Surveillance Schedule

• Cystoscopy at 3 months after re-TURBT (this is critical - a positive 3-month cystoscopy is a strong predictor of progression)
• Then every 3-6 months for 2 years
• Then annually for life (given recurrence history)
• CT Urography is also recommended to evaluate the upper urinary tract, as urothelial tumors can be multifocal

4. Urine Cytology

• Perform urine cytology at baseline and at each follow-up cystoscopy
• Cytology is particularly important to detect concurrent CIS (carcinoma in situ), which is a high-risk feature

Summary Flowchart

Current Report: T1 LG (lamina invasion, no muscle invasion)
        ↓
Re-TURBT in 2-6 weeks (mandatory)
        ↓
  ┌─────────────────────────────────┐
  │ Re-TURBT Result                 │
  ├──────────────┬──────────────────┤
  │ T1 or Ta     │ T2 (upstaged)    │
  │ (NMIBC)      │ (MIBC)           │
  ↓              ↓
BCG induction +  Radical cystectomy
maintenance      + Neoadjuvant chemo
  ↓
Surveillance cystoscopy
(3 mo → 6 mo → annual)

Clinical Note

Lipid Profile Analysis

Key Clinical Decision Point: LDL = 190 mg/dL

"For patients aged 20-75 with LDL-C ≥190 mg/dL, high-intensity statin therapy should be initiated without calculating 10-year ASCVD risk."

First-Line Statin: Rosuvastatin (Preferred)

Drug of Choice: Rosuvastatin 20 mg daily

1. Greater LDL-lowering per mg - Rosuvastatin is the most potent LDL-lowering statin mg-for-mg (approximately 10-15% more LDL reduction than equivalent atorvastatin doses)
2. Better HDL raising effect - HDL is borderline low at 44 mg/dL; rosuvastatin raises HDL more than atorvastatin
3. Triglyceride lowering - Also lowers TG effectively (his TG is 191 mg/dL, mildly elevated)
4. Age 35, no comorbidities - Rosuvastatin has an excellent safety profile with minimal drug interactions (hydrophilic statin, less CYP3A4 metabolism)
5. Simulated trial data suggest rosuvastatin should be preferred over atorvastatin as the high-intensity statin for LDL >190 mg/dL
6. Start at 20 mg (not 40 mg) since this is initiation - can uptitrate to 40 mg if LDL target not met

LDL Target

• Goal LDL: <100 mg/dL (primary prevention, no ASCVD)
• Ideally <70 mg/dL if FH is confirmed
• Recheck fasting lipid profile in 4-12 weeks after starting therapy

Additional Management

1. Rule out Familial Hypercholesterolemia (FH):
   • LDL 190 in a 35-year-old with rising trend - use the Dutch Lipid Clinic Network criteria or Simon Broome criteria
   • Check family history of premature CVD, tendon xanthomas, corneal arcus
   • If FH confirmed, LDL target becomes <70 mg/dL and statin alone may be insufficient long-term
2. Lifestyle modification (concurrent, not instead of statin):
   • Dietary: reduce saturated fat (<7% of calories), eliminate trans fats, increase soluble fiber
   • Exercise: 150 min/week moderate aerobic activity
   • Weight management
3. Thyroid function (TSH): Rule out hypothyroidism as a secondary cause of dyslipidemia - especially in a young patient with no obvious dietary cause
4. If LDL remains >100 mg/dL on maximally tolerated statin: Add ezetimibe 10 mg (next step per ACC/AHA guidelines)
5. Vitamin D: Currently 31.6 ng/mL (borderline low) - maintain supplementation to keep levels >40 ng/mL, as low Vitamin D is associated with higher cardiovascular risk
6. Vitamin B12: 265 pg/mL (low-normal at the lower end of range) - monitor, especially if diet is predominantly vegetarian

Summary

First-Line Statin: Rosuvastatin 20 mg daily

Why High-Intensity Statin is Mandatory (No Risk Calculator Needed)

Lipid Summary

Drug of Choice: Rosuvastatin

Why Rosuvastatin Over Atorvastatin

• Can uptitrate to 40 mg if LDL target not achieved
• Recheck fasting lipid profile in 4-12 weeks

LDL Target

• <100 mg/dL (primary prevention, no ASCVD)
• <70 mg/dL if Familial Hypercholesterolemia (FH) is confirmed

If LDL Remains >100 mg/dL on Maximum Statin

Additional Notes

• TSH: Check to rule out hypothyroidism as a secondary cause of dyslipidemia
• Lifestyle: Low saturated fat diet, aerobic exercise 150 min/week - concurrent with statin, not a substitute
• Vitamin D 31.6 ng/mL - borderline; supplement to maintain >40 ng/mL
• Vitamin B12 265 pg/mL - low-normal; monitor, especially if vegetarian diet

Recent Studies: Rosuvastatin vs. Atorvastatin Efficacy

1. Zhou et al., Annals of Internal Medicine (2024) - Largest Real-World Study

• Design: Real-world target trial emulation; >8 million Chinese patients (CRDS) + ~500,000 UK Biobank patients; 1:1 propensity-score matched
• Primary outcome: 6-year all-cause mortality

• Key finding: Rosuvastatin showed lower mortality, lower MACE and lower liver outcomes than atorvastatin, but was associated with higher risk of new-onset diabetes
• Relevance to your patient: At age 35 with no diabetes currently, the diabetes signal with rosuvastatin is a noteworthy long-term consideration, though risk remains low in a non-obese, non-prediabetic young individual

2. LODESTAR Trial - BMJ (2023)

• Design: RCT, patients with established coronary artery disease (CAD), rosuvastatin vs. atorvastatin, 3-year follow-up
• Key findings:
  • Rosuvastatin was not superior to atorvastatin in preventing MACE at 3 years
  • More patients on rosuvastatin achieved LDL <70 mg/dL (despite similar MACE)
  • Rosuvastatin group had higher incidence of new diabetes medications and more cataract operations
• ACC interpretation: "High-intensity atorvastatin therapy may be preferential to rosuvastatin" in CAD patients based on this trial
• Caveat: This was a secondary prevention (CAD) population - not applicable to a young, primary prevention patient like yours

3. Khokhar et al., JPMA (2022) - RCT [PMID: 37013304]

• Design: Double-blind RCT, 66 patients with T2DM; rosuvastatin 10 mg vs. atorvastatin 10 mg for 4 months
• Results:
  • At 1 month: rosuvastatin achieved European LDL goal in 51% vs. 46% with atorvastatin (p<0.0001)
  • At 4 months: 94% vs. 88% goal achievement (p<0.05)
• Conclusion: Rosuvastatin was significantly more efficacious than atorvastatin at equivalent doses for LDL reduction

4. Prasadu et al., Eur J Cardiovascular Medicine (2023-24) - RCT

• Design: RCT, 100 patients, 12-week follow-up, rosuvastatin vs. atorvastatin 20 mg each
• Results:
  • Rosuvastatin: LDL reduced from 160 → 80 mg/dL (50% reduction, p<0.001)
  • Atorvastatin: LDL reduced from 158 → 95 mg/dL (39.9% reduction, p<0.001)
  • Rosuvastatin significantly more effective (p<0.001)
  • Adverse events: 12% (rosuvastatin) vs. 16% (atorvastatin) - rosuvastatin was also safer

5. Huang et al., EClinicalMedicine (2026) [PMID: 41509616]

• Found rosuvastatin superior for cardiovascular outcomes across CKD stages
• Reinforces rosuvastatin's cardiorenal protective advantage in high-risk subgroups

Synthesis: What the Evidence Tells Us for Your 35-Year-Old Patient

Rosuvastatin + Fenofibrate in This Patient: Clinical Assessment

First - Is the Combination Justified by the Lipid Profile?

What Fenofibrate Would Actually Do Here

• Reduces TG by 30-50% (191 → ~100-130 mg/dL range)
• Raises HDL by 5-15% (44 → ~47-50 mg/dL)
• Has modest or neutral effect on LDL - it does not replace statin therapy for LDL lowering

Guideline Position on Statin + Fenofibrate Combination

Safety Concerns: FDA FAERS Analysis (Li et al., Frontiers 2025)

What Should Be Used Instead for the TG/HDL Component?

Recommendation for This Patient

Step 1 (Now):         Rosuvastatin 20 mg/night
                      + Aggressive lifestyle modification
                      + Recheck lipids in 4-12 weeks

Step 2 (if TG persists >150 on statin):
                      Add pure EPA (icosapentaenoic acid 4g/day)
                      - NOT fenofibrate as first add-on

Step 3 (only if TG >500):
                      Fenofibrate may be considered with close
                      CK and LFT monitoring